Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers

Furugaki,Koh; Iwai,Toshiki; Kondoh,Kumiko; Moriya,Yoichiro; Mori,Kazushige

doi:10.3892/ol_00000041

Antitumor activity of erlotinib in combination with gemcitabine in in vitro and in vivo models of KRAS-mutated pancreatic cancers

Authors:
- Koh Furugaki
- Toshiki Iwai
- Kumiko Kondoh
- Yoichiro Moriya
- Kazushige Mori
View Affiliations

Affiliations: Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd., Kanagawa 247-8530, Japan
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000041
Pages: 231-235

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erlotinib treatment in combination with gemcitabine is a standard therapy for patients with locally advanced pancreatic cancer in many countries, including the US and the EU. Since mutations of the K-ras oncogene (KRAS) occur in approximately 90% of pancreatic cancers, we examined the antitumor activity of erlotinib in combination with gemcitabine in KRAS-mutated pancreatic cancer cell lines, HPAC and Capan-1, which have the KRAS mutation G12D and G12V, respectively. We analyzed the mode of inhibition of in vitro tumor cell proliferation by means of a combination index and found that a combination treatment of erlotinib plus gemcitabine had an additive effect in the two cell lines. We then examined the effect of erlotinib and gemcitabine on the phosphorylation of epidermal growth factor receptor (EGFR). Erlotinib strongly suppressed, while gemcitabine augmented the phosphorylation of EGFR, which was completely blocked by erlotinib in the two cell lines. An in vivo tumor growth inhibition test was then performed using the HPAC tumor xenograft model. The combination therapy of erlotinib and gemcitabine resulted in a significant inhibition of tumor growth compared with erlotinib or gemcitabine monotherapy. To the best of our knowledge, this is the first study to show the combination effect of erlotinib and gemcitabine in vivo using a xenograft model of a KRAS-mutated pancreatic cancer cell line.

View Figures

View References

1	Wanebo HJ and Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer. 78:580–591. 1996. View Article : Google Scholar : PubMed/NCBI
2	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
3	Van Cutsem E, Verslype C and Grusenmeyer PA: Lessons learned in the management of advanced pancreatic cancer. J Clin Oncol. 25:1949–1952. 2007.PubMed/NCBI
4	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and Parulekar W: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
5	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
6	Dancey J and Sausville EA: Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2:296–313. 2003. View Article : Google Scholar : PubMed/NCBI
7	Ueda S, Ogata S, Tsuda H, Kawarabayashi N, Kimura M, Sugiura Y, Tamai S, Matsubara O, Hatsuse K and Mochizuki H: The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas. 29:e1–8. 2004. View Article : Google Scholar
8	Lee J, Jang K-T, Ki C-S, Lim T, Park YS, Lim HY, Choi D-W, Kang WK, Park K and Park JO: Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 109:1561–1569. 2007. View Article : Google Scholar : PubMed/NCBI
9	Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol. 23:6829–6837. 2005. View Article : Google Scholar : PubMed/NCBI
10	Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554. 1988. View Article : Google Scholar : PubMed/NCBI
11	Lohr M, Kloppel G, Maisonneuve P, Lowenfels AB and Luttges J: Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia. 7:17–23. 2005. View Article : Google Scholar : PubMed/NCBI
12	Moore MJ, da Cunha Santos G, Kamel-Reid S, Chin K, Tu D, Parulekar W, Ludkovski O, Squire J, Richardson F and Tsao M: The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib in the National Cancer Institute of Canada Clinical Trials Group trial study PA.3. Proc ASCO. 25:abs 45212007.
13	Dowell J, Minna JD and Kirkpatrick P: Erlotinib hydrochloride. Nat Rev Drug Discov. 4:13–14. 2005. View Article : Google Scholar : PubMed/NCBI
14	Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J and Lawrence TS: The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 14:5142–5149. 2008. View Article : Google Scholar : PubMed/NCBI
15	Ng SS, Tsao MS, Nicklee T and Hedley DW: Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther. 1:777–783. 2002.PubMed/NCBI
16	Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55. 1984. View Article : Google Scholar : PubMed/NCBI
17	Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N and Nishio K: Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib (‘Iressa’) and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer. 108:464–472. 2004.
18	Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS and Nyati MK: Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res. 66:981–988. 2006. View Article : Google Scholar : PubMed/NCBI
19	Mendelsohn J and Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene. 19:6550–6565. 2000. View Article : Google Scholar : PubMed/NCBI
20	Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J and Lawrence TS: Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res. 65:6835–6842. 2005. View Article : Google Scholar : PubMed/NCBI
21	Wang X, McCullough KD, Franke TF and Holbrook NJ: Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival. J Biol Chem. 275:14624–14631. 2000. View Article : Google Scholar : PubMed/NCBI
22	Miyazaki Y, Hiraoka S, Tsutsui S, Kitamura S, Shinomura Y and Matsuzawa Y: Epidermal growth factor receptor mediates stress-induced expression of its ligands in rat gastric epithelial cells. Gastroenterology. 120:108–116. 2001. View Article : Google Scholar : PubMed/NCBI
23	Mahaffey CM, Davies AM, Lara PN Jr, Pryde B, Holland W, Mack PC, Gumerlock PH and Gandara DR: Schedule-dependent apoptosis in K-ras mutant non-small cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer. 8:548–553. 2007. View Article : Google Scholar : PubMed/NCBI
24	Ling YH, Li T, Yuan Z, Haigentz M Jr, Weber TK and Perez-Soler R: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small cell lung cancer cell lines. Mol Pharmacol. 72:248–258. 2007. View Article : Google Scholar